In a new study, scientists discovered two FDA-approved cancer drugs that could also be effective at combatting one well-known ...

A new study shows that lecanemab, an amyloid-clearing Alzheimer’s therapy, does not improve the brain’s waste-removal network ...

In an effort to combat Alzheimer's disease, scientists are looking at existing drugs that could treat the condition, and a ...

Medically reviewed by Smita Patel, DO Some commonly used medications have been linked to memory issues and severe ...

Researchers found that lecanemab, the Alzheimer’s drug designed to clear amyloid-β plaques, does not improve the brain’s waste clearance system in the short term.

Washington University Medicine in St. Louis is conducting important research into treating early-onset Alzheimer's before ...

A newly approved blood test can help rule out some cases based on the amount of amyloid in the brain. A neurology professor ...

For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.

The roadmap to fighting Alzheimer’s disease is a matter of updating government policy to match the current science.

A new study offers a concrete, testable explanation for why Alzheimer’s patients often stop recognizing their loved ones.